Pfizer’s First Global Drug Development Center in Asia to be Set up in India

CHENNAI, (IANS) – Global pharma giant Pfizer, which developed the mRNA-based vaccine against Covid, on May 4 announced setting up a global drug development center to boost critical research and development in India.

The 61,000 sq ft research and technology center will be set up at the IIT Madras Research Park here, the company said. Pfizer said it has invested more than Rs 150 crore in it.

While this center will be a part of a network of 12 global centers set up worldwide, it is the first and only one at present being set up by Pfizer in Asia.

The center will include the development of both, active pharmaceutical ingredients and finished dosage forms of differentiated products such as complex/value-added formulations, controlled-release dosage forms, device-combination products, lyophilized injections, powder-fill products, and ready-to-use formulations.

It will also develop and support products in global markets and Pfizer’s manufacturing centers worldwide.